NC
CRL icon

nVerses Capital’s Charles River Laboratories CRL Stock Holding History

nVerses Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225K Buy
+991
New +$176K 0.35% 158

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

nVerses Capital's CRL Position: Q2 2026 in Review

nVerses Capital opened a new position in Charles River Laboratories (CRL) in Q2 2026: 991 shares worth $225K. The stake represents 0.35% of the portfolio and ranks #158 among its holdings.

436 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • nVerses Capital held 991 shares of Charles River Laboratories worth $225K as of Q2 2026.
  • Charles River Laboratories was a new nVerses Capital position in Q2 2026.
  • Charles River Laboratories made up 0.35% of nVerses Capital's portfolio in Q2 2026, its #158 holding.
  • 436 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.